Treatment of hypertension in dialysis and essential hypertension patients with nifedipine.

H E Eliahou, A Iaina, R Schneider, D Cohen, D Goldfarb, M Gross
{"title":"Treatment of hypertension in dialysis and essential hypertension patients with nifedipine.","authors":"H E Eliahou,&nbsp;A Iaina,&nbsp;R Schneider,&nbsp;D Cohen,&nbsp;D Goldfarb,&nbsp;M Gross","doi":"10.3109/08860228209049856","DOIUrl":null,"url":null,"abstract":"<p><p>The immediate antihypertensive effect of 10 mg nifedipine sublingually (nifedipine test), was measured in 19 chronic renal failure hypertensive patients on dialysis and 34 essential hypertensive patients with normal kidney function. The blood pressure decreased significantly in both groups. The minimal values were observed between 30 and 60 minutes after the sublingual administration of nifedipine. The blood pressure decreased from 178 +/- 3.3/104.0 +/- 3.9 to 136.0 +/- 4.7/87.5 +/- 5.1 mm Hg (p less than 0.001) in dialysis patients and from 176.8 +/- 4.5/107.1 +/- 2.4 to 133.0 +/- 3.0/81.7 +/- 2.2 mm Hg in essential hypertension patients (p less than 0.001). The decrease in blood pressure during the test had a significant positive correlation with the pre-test values. Thirteen hypertensive patients on dialysis and 20 essential hypertensive patients completed 2 weeks of daily oral nifedipine therapy, with a dose of 30 to 40 mg per day. The mean blood pressure at the end of the 2 weeks of treatment decreased from 179.5 +/- 4.5/108.5 +/- 5.3 mm Hg to 154.4 +/- 6.3/82.3 +/- 2.6 mm Hg (p less than 0.001) in dialysis patients, and from 176.8 +/- 5.8/110.3 +/- 2.9 to 151.3 +/- 5.3/93.5 +/- 2.6 mm Hg (p less than 0.001) in essential hypertension patients. The present results reveal that nifedipine has a powerful immediate as well as a long-term antihypertensive action in dialysis patients with high blood pressure. This effect is similar to that obtained in essential hypertensive patients.</p>","PeriodicalId":79208,"journal":{"name":"Clinical and experimental dialysis and apheresis","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"1982-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3109/08860228209049856","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and experimental dialysis and apheresis","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3109/08860228209049856","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 5

Abstract

The immediate antihypertensive effect of 10 mg nifedipine sublingually (nifedipine test), was measured in 19 chronic renal failure hypertensive patients on dialysis and 34 essential hypertensive patients with normal kidney function. The blood pressure decreased significantly in both groups. The minimal values were observed between 30 and 60 minutes after the sublingual administration of nifedipine. The blood pressure decreased from 178 +/- 3.3/104.0 +/- 3.9 to 136.0 +/- 4.7/87.5 +/- 5.1 mm Hg (p less than 0.001) in dialysis patients and from 176.8 +/- 4.5/107.1 +/- 2.4 to 133.0 +/- 3.0/81.7 +/- 2.2 mm Hg in essential hypertension patients (p less than 0.001). The decrease in blood pressure during the test had a significant positive correlation with the pre-test values. Thirteen hypertensive patients on dialysis and 20 essential hypertensive patients completed 2 weeks of daily oral nifedipine therapy, with a dose of 30 to 40 mg per day. The mean blood pressure at the end of the 2 weeks of treatment decreased from 179.5 +/- 4.5/108.5 +/- 5.3 mm Hg to 154.4 +/- 6.3/82.3 +/- 2.6 mm Hg (p less than 0.001) in dialysis patients, and from 176.8 +/- 5.8/110.3 +/- 2.9 to 151.3 +/- 5.3/93.5 +/- 2.6 mm Hg (p less than 0.001) in essential hypertension patients. The present results reveal that nifedipine has a powerful immediate as well as a long-term antihypertensive action in dialysis patients with high blood pressure. This effect is similar to that obtained in essential hypertensive patients.

硝苯地平治疗透析高血压及原发性高血压患者。
本文对19例透析治疗的慢性肾功能衰竭高血压患者和34例肾功能正常的原发性高血压患者进行了10 mg硝苯地平舌下降压(硝苯地平试验)试验。两组患者的血压均显著下降。最小值是在硝苯地平舌下给药后30 - 60分钟观察到的。透析患者血压从178 +/- 3.3/104.0 +/- 3.9降至136.0 +/- 4.7/87.5 +/- 5.1 mm Hg (p < 0.001),原发性高血压患者血压从176.8 +/- 4.5/107.1 +/- 2.4降至133.0 +/- 3.0/81.7 +/- 2.2 mm Hg (p < 0.001)。测试期间血压的下降与测试前值有显著的正相关。13例透析高血压患者和20例原发性高血压患者完成了2周的每日口服硝苯地平治疗,剂量为30 ~ 40mg /天。治疗2周结束时,透析患者的平均血压从179.5 +/- 4.5/108.5 +/- 5.3 mm Hg降至154.4 +/- 6.3/82.3 +/- 2.6 mm Hg (p < 0.001),原发性高血压患者的平均血压从176.8 +/- 5.8/110.3 +/- 2.9降至151.3 +/- 5.3/93.5 +/- 2.6 mm Hg (p < 0.001)。目前的研究结果表明,硝苯地平对透析合并高血压患者具有强大的即时和长期降压作用。这种效果与原发性高血压患者相似。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信